A Nanocrystal Biosensor for Detection of Multiple TBI Neurochemical Biomarkers

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$199,984.00
Award Year:
2007
Program:
SBIR
Phase:
Phase I
Contract:
1R43NS056848-01A1
Award Id:
85915
Agency Tracking Number:
NS056848
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
NANOMATERIALS AND NANOFABRICATION LABS, P.O. BOX 2168, FAYETTEVILLE, AR, 72702
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
030498609
Principal Investigator:
YONGCHENGLIU
(479) 575-3481
YCLIU@NN-LABS.COM
Business Contact:
YONGCHENGLIU
() -
ycliu@nn-labs.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): This SBIR proposal intends to develop a nanocrystal biosensor, which is capable of simultaneously detecting and quantifying multiple traumatic brain injury (TBI)-specific biomarkers in relatively small volumes of whole blood (0.1-1 uL). The biosensor design utilizes the well-known size dependent photoluminescence (PL) of the semiconductor nanocrystals to label monoclonal antibodies for these brain injury-specific biomarkers such as S-100a, D- Dimer, and CRP, etc . The s emiconductor nanocrystals as biolabels make the biosensor able to simultaneously detect multiple TBI-specific neurochemical biomarkers in one setup with a single light source due to their broad excitation spectra, and their narrow, symmetric emission spect ra. A membrane filter, immobilized with multiple monoclonal antibodies, will be used as a bioseparator to specifically capture and separate these multiple TBI-specific neurochemical biomarkers from the sample while going through the microflow cell. The sim ultaneous detection and quantification of multiple brain injury-specific biomarkers will subsequently be accomplished by the differently sized semiconductor nanocrystal biolabeled antibodies. The simultaneous detection of multiple TBI-specific neurochemica l biomarkers diminishes the false signal and improves the accuracy in assessing TBI. In comparison to existing technologies such as ELISA, this new technology will be more sensitive, reliable, specific, accurate, portable, robust, inexpensive and rapider t o assess TBI.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government